OBJECTIVE: To evaluate the clinical utility of lung radiofrequency ablation (RFA) in patients with unresectable pulmonary metastasis from renal cell carcinoma (RCC). PATIENTS AND METHODS: We retrospectively examined 39 patients with unresectable metastases from RCC who were treated with lung RFA. Patients with six or fewer lung metastases measuring < or =6 cm that were confined in the lung, had all lung tumours ablated (curative ablation). Patients with extrapulmonary lesions, seven or more lung tumours, or large tumours of >6 cm, had mass reduction (palliative ablation). The primary endpoints was the overall survival, secondary endpoints were safety, local tumour progression rate, and recurrence-free survival in the curative ablation group. RESULTS: There were significant differences in the overall survival rates between the curative and palliative groups at 1 year (100% vs 90%), 3 years (100% vs 52%) and 5 years (100% vs 52%) (P < 0.05). The maximum lung tumour diameter was also a significant prognostic factor. There was local tumour progression in 13 patients (33%) during the mean follow-up of 25 months. The recurrence-free survival rates were 92% at 1 year, 23% at 3 years and 23% at 5 years in the curative ablation group. Pneumothorax requiring chest tube placement (six of 89, 7%) and pneumonia (one of 89, 1%) were major complications. CONCLUSION: Lung RFA is a safe and effective treatment for prolonging survival in patients with unresectable RCC lung metastases.
OBJECTIVE: To evaluate the clinical utility of lung radiofrequency ablation (RFA) in patients with unresectable pulmonary metastasis from renal cell carcinoma (RCC). PATIENTS AND METHODS: We retrospectively examined 39 patients with unresectable metastases from RCC who were treated with lung RFA. Patients with six or fewer lung metastases measuring < or =6 cm that were confined in the lung, had all lung tumours ablated (curative ablation). Patients with extrapulmonary lesions, seven or more lung tumours, or large tumours of >6 cm, had mass reduction (palliative ablation). The primary endpoints was the overall survival, secondary endpoints were safety, local tumour progression rate, and recurrence-free survival in the curative ablation group. RESULTS: There were significant differences in the overall survival rates between the curative and palliative groups at 1 year (100% vs 90%), 3 years (100% vs 52%) and 5 years (100% vs 52%) (P < 0.05). The maximum lung tumour diameter was also a significant prognostic factor. There was local tumour progression in 13 patients (33%) during the mean follow-up of 25 months. The recurrence-free survival rates were 92% at 1 year, 23% at 3 years and 23% at 5 years in the curative ablation group. Pneumothorax requiring chest tube placement (six of 89, 7%) and pneumonia (one of 89, 1%) were major complications. CONCLUSION: Lung RFA is a safe and effective treatment for prolonging survival in patients with unresectable RCC lung metastases.
Authors: Gianpaolo Carrafiello; Gianlorenzo Dionigi; Luigi Boni; Monica Mangini; Anna Maria Ierardi; Filippo Piacentino; Annalisa Di Massa; Larissa Nocchi Cardim; Antonio Biondi; Carlo Fugazzola Journal: Updates Surg Date: 2011-11-08
Authors: G Carrafiello; M Mangini; F Fontana; A Di Massa; A M Ierardi; E Cotta; F Piacentino; L Nocchi Cardim; C Pellegrino; C Fugazzola Journal: Radiol Med Date: 2011-10-21 Impact factor: 3.469
Authors: M Macchi; M P Belfiore; C Floridi; N Serra; G Belfiore; L Carmignani; R F Grasso; E Mazza; C Pusceddu; L Brunese; G Carrafiello Journal: Med Oncol Date: 2017-04-18 Impact factor: 3.064